ECHA’s Member State Committee (MSC) disagrees to identify resorcinol as a substance of very high concern (SVHC) due to its endocrine-disrupting properties. Now, the Commission's REACH Committee will make a final decision.
Commission to Prepare a Draft Proposal
At its June meeting, the Member State Committee did not unanimously support France’s proposal to identify resorcinol (EC 203-585-2; CAS 108-46-3) as an SVHC. However, the committee acknowledged that there is scientific evidence that resorcinol is an endocrine disruptor as defined by the World Health Organization (WHO).
After receiving the MSC’s opinion, the Commission has three months to prepare a draft proposal on the identification as an SVHC and will then make a final decision in its committee procedure.
Resorcinol Used to Manufacture Cosmetics
Resorcinol is used to manufacture rubber compounds, resins and coatings, as well as cosmetics. It is the first substance proposed as an SVHC because of its thyroid disrupting effects in humans.
A majority of the committee members concluded that there is scientific evidence of probable serious effects to human health due to hypothyroidism and potential neurodevelopmental effects during pregnancy. However, a few members expressed different views on whether the substance is of equivalent level of concern.
Source: ECHA